Core Viewpoint - The company Shiyao Group has received approval from the National Medical Products Administration of the People's Republic of China for its self-developed drug SYH2066, which targets respiratory syncytial virus (RSV) and is set to enter clinical trials in China by September 2025 [1] Company Summary - SYH2066 is a new chemical entity classified as a Class 1 new drug, specifically designed as an oral small molecule candidate for treating respiratory infections caused by RSV [1] - The drug has demonstrated good oral bioavailability and favorable pharmacokinetic properties in preclinical studies, significantly reducing RSV viral load in animal models while showing high safety [1] - Currently, there are no targeted small molecule drugs for RSV available in the domestic and international markets, positioning SYH2066 as a potentially effective treatment with high clinical development value [1] Industry Summary - The approval of SYH2066 marks a significant advancement in the treatment options for RSV, a disease that currently lacks targeted small molecule therapies [1] - The development of this drug could address a critical gap in the market, potentially leading to improved patient outcomes and establishing a new standard of care for RSV infections [1]
石药集团(01093)：SYH2066片在中国获临床试验批准